Viral dosing of influenza A infection reveals involvement of RIPK3 and FADD, but not MLKL

• Main Authors: Teodora Oltean, Emily Van San, Tatyana Divert, Tom Vanden Berghe, Xavier Saelens, Jonathan Maelfait, Nozomi Takahashi, Peter Vandenabeele
• Format: Article
• Language: English
• Published: Nature Publishing Group 2021-05-01
• Series: Cell Death and Disease
• Online Access: https://doi.org/10.1038/s41419-021-03746-0

Abstract RIPK3 was reported to play an important role in the protection against influenza A virus (IAV) in vivo. Here we show that the requirement of RIPK3 for protection against IAV infection in vivo is only apparent within a limited dose range of IAV challenge. We found that this protective outcome is independent from RIPK3 kinase activity and from MLKL. This shows that platform function of RIPK3 rather than its kinase activity is required for protection, suggesting that a RIPK3 function independent of necroptosis is implicated. In line with this finding, we show that FADD-dependent apoptosis has a crucial additional effect in protection against IAV infection. Altogether, we show that RIPK3 contributes to protection against IAV in a narrow challenge dose range by a mechanism that is independent of its kinase activity and its capacity to induce necroptosis.